Navigation Links
Nile Therapeutics Reports 2012 First Quarter Financial Results
Date:5/15/2012

eliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's immediate need to raise additional capital to fund its general corporate activities and its need to raise substantial additional capital to fund its planned Phase 2 study of cenderitide and to otherwise fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission on April 2, 2012. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.Condensed Statement of OperationsThree months ended March 31,20122011Income:Collaboration income$
95,500$
-Operating expenses:Research and development465,353622,332General and administrative500,020575,278Total operating expenses965,3731,197,610Loss from operations(769,873)(1,197,610)Other income (expense):Interest income2441,986Other income (expense)(2,250)(168)Total other income (expense) (2,006)1,818Net loss$
(771,879)$
(1,195,792)Basic and diluted loss per share$
(0.02)$
(0.03)Weighted-average common shares outstanding39,712,23134,673,475Summary Balance Sheet(in thousands)March 31,  2012December 31, 2011Cash and cash equivalents $
436$   1,039Work
'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 5. März 2015 Unfors ... im Bereich diagnostische Röntgenstrahlung, stellte heute ... dem European Congress of Radiology (ECR) ... Österreich, einen neuen Strahlungsüberwachungssensor vor. ... Der RaySafe X2-Überwachungssensor ...
(Date:3/4/2015)... Holdings, Inc. (NYSE: HRC ) announced today ... to its Board of Directors.  She most recently served ... as President of Covidien,s Vascular Therapies Division from 2012 to ... 2012. Ms. Enxing Seng joined Covidien in ... she was a founding member and executive officer responsible ...
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
Breaking Medicine Technology:Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 3Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7
(Date:3/5/2015)... March 05, 2015 Afterglow®, a ... wave technology has just been rated #1 in ... A Boyfriend.” Developed by urogynecologist Dr. Ralph Zipper, ... levels of arousal by themselves and with their ... light technology to enhance a women's sensual experience ...
(Date:3/5/2015)... TULSA, OK (PRWEB) March 05, 2015 ... been to build a faster, safer, smarter commercial lifting ... the company has an increasing role in more ... lifting systems last month – Octapad System for lifting ... place concrete barriers during road construction projects. , ...
(Date:3/5/2015)... 05, 2015 ThermiHealth today announces ... for OB-GYNs and Urogynecologists. ThermiVa is a unique ... dermatological application in aesthetics and other medical specialties. ... non-invasive, in-office procedure, and patients reporting excitement about ... results without surgery. ThermiVa was developed by ThermiGyn, ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 In recognition ... to help patients, Soho Flordis International (SFI) has been ... SFI is a global natural medicine company committed to ... evidence of quality, safety, and effectiveness. For these efforts ... E. Tyler Commercial Investment in Phytomedicinal Research Award. ...
(Date:3/5/2015)... 05, 2015 Hoggan Scientific, ... ergoFET physical therapy, ergonomic force gauges, and ... ergonomics, engineering, and research applications, introduced ... available at http://www.HogganHealth.net . The new ... healthcare professionals a handgrip muscle strength testing ...
Breaking Medicine News(10 mins):Health News:Doctor’s Afterglow® Vibrator Enhances Women’s Arousal Using Light Waves, Ranks #1 In "Sex Toys That Are Better Than A Boyfriend" 2Health News:New Vacuworx Concrete Lifting Systems Aid Safer, Greener Environment As Contractors Seek LEED Incentives 2Health News:New Vacuworx Concrete Lifting Systems Aid Safer, Greener Environment As Contractors Seek LEED Incentives 3Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 3Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 3Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2
... WASHINGTON, Dec. 21 The new Secretary of,Veterans Affairs ... those hospitalized in VA facilities, during the,holiday season and ... be unable to be with their families during,the holidays," ... "The,good cheer and spirit of compassion during the season ...
... research suggests , FRIDAY, Dec. 21 (HealthDay News) -- Treating ... concludes a University of Pennsylvania School of Medicine study in ... , It found that providing depression care management to older ... over five years by about 50 percent. , "Depression is ...
... workflow and data connectivity for ambulatory care ... ... Wash., Dec. 21 Cardiac Science,Corporation, (Nasdaq: CSCX ), ... that it completed the,connectivity of its HeartCentrix(R) ECG informatics software ...
... Partners with Kashi, America,s Milk Processors and, Bally Total ... the ... the Participant --, SILVER SPRING, Md., Dec. 21 ... the obesity epidemic,with its biggest and best year yet, with ...
... of providing comprehensive screening and diagnostic services to under-or ... cervical cancer for treatment. Dr. Donatus U. Ekwueme of ... Promotion at the Centers for Disease Control and Prevention ... of screening a woman for breast cancer was $94, ...
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), announced today ... to the U.S. Food and Drug Administration (FDA) ... for Xibrom QD,as a treatment for inflammation, pain, ... solution), Xibrom is a topical non-steroidal anti-inflammatory ...
Cached Medicine News:Health News:VA Salutes Volunteers' Spreading Holiday Cheer 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 2Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 3Health News:Study determines costs of breast and cervical cancer detection among low-income women 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2
... The microprocessor controlled, Blanketrol ... therapy system provides effective patient ... one system! The Blanketrol II ... highest flow rates of any ...
Inquire...
Inquire...
... and accurate immunoassay for the quantification of ... fully automated Elecsys proBNP assay helps to ... NT-proBNP levels also indicate the severity of ... prognosis. In addition, NT-proBNP facilitates monitoring, allowing ...
Medicine Products: